Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0L6DA
|
||||
Former ID |
DAP001541
|
||||
Drug Name |
Valdecoxib
|
||||
Synonyms |
Bextra; COX; Kudeq; Valdyn; Pfizer brand of valdecoxib; Valdecoxib [USAN]; SC 65872; ND-0214; SC-65872; YM-974; Valdecoxib (USAN/INN); P-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-(9CI); 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Antiinflammatory Agents
|
||||
Structure |
Download2D MOL |
||||
Formula |
C16H14N2O3S
|
||||
InChI |
InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)
|
||||
InChIKey |
LNPDTQAFDNKSHK-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 181695-72-7
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
587378, 841634, 7300492, 7979620, 10238560, 11364641, 11367203, 11369765, 11372040, 11374755, 11377927, 11484171, 11488324, 11490816, 11492943, 11495561, 11528781, 11538199, 12015079, 14850214, 17137106, 17396876, 26612701, 26680171, 26719834, 26748964, 26748965, 29300443, 46386621, 46393843, 46506229, 46513481, 47885663, 48110737, 49665731, 49666068, 49681792, 50107497, 53789038, 57339580, 57578333, 58107175, 75154431, 85789263, 88531863, 92124765, 92308537, 92714410, 99444047, 103225393
|
||||
SuperDrug ATC ID |
M01AH03
|
||||
SuperDrug CAS ID |
cas=181695727
|
||||
Target and Pathway | |||||
Target(s) | Prostaglandin G/H synthase 2 | Target Info | Inhibitor | [536232] | |
KEGG Pathway | Arachidonic acid metabolism | ||||
Metabolic pathways | |||||
NF-kappa B signaling pathway | |||||
VEGF signaling pathway | |||||
TNF signaling pathway | |||||
Retrograde endocannabinoid signaling | |||||
Serotonergic synapse | |||||
Ovarian steroidogenesis | |||||
Oxytocin signaling pathway | |||||
Regulation of lipolysis in adipocytes | |||||
Leishmaniasis | |||||
Pathways in cancer | |||||
Chemical carcinogenesis | |||||
MicroRNAs in cancer | |||||
Small cell lung cancer | |||||
PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
References | |||||
Ref 536232 | Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. | ||||
Ref 539917 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2894). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.